AstraZeneca Pharma India has disclosed in a regulatory filing that it intends to sell its Bengaluru production site. It stated that as part of its ongoing strategic evaluation, the business intends to eventually close its Bengaluru manufacturing plant. AstraZeneca Pharma acknowledges that their primary duty is to their workforce.
“AstraZeneca Pharma India Limited (Company) remains committed to advance access to innovative medicines in India, with a clear ambition to be pioneers in science, lead in specialist disease areas, and transform patient outcomes. As a part of AstraZeneca's ongoing strategic review of its Global Manufacturing and Supply Network, the Company intends to exit the manufacturing site in Bangalore, in due course,” it said in the filing.
In addition to putting the manufacturing facility up for sale, the company will start looking for a buyer who can serve as a Contract Manufacturing Organisation (CMO) for the goods that are currently produced or packaged at the Bengaluru location. AztraZeneca stated that the proposals need to have the required statutory permissions.
It further added, “The company is fully cognizant of the impact this change can bring and its first responsibility will be towards its employees and meeting the needs of its patients by ensuring an uninterrupted supply of medicines.”
AstraZeneca India was founded in 1979 and has its headquarters in Bengaluru. The listed operational business, AstraZeneca Pharma India Limited (AZPIL), is a division of AstraZeneca Plc, UK. According to their website, AstraZeneca India employs more than 1,400 people nationwide.
AstraZeneca Pharma India is largely focused on four therapy areas: oncology, cardiovascular, renal, metabolic, and respiratory. It also develops and commercialises prescription medications.
